2seventy bio, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- William D. Baird III,
- Full Time Employees
- 65
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 60 Binney Street Cambridge MA United States of America 02142
- IPO Date
- Nov 3, 2021
- CIK
- 0001860782
- Website
- 2seventybio.com
- Similar Companies
- Business
- 2seventy bio, Inc. (Nasdaq: TSVT) is a cell and gene therapy company focused on the research, development and commercialization of transformative treatments for cancer, primarily in the United States; its core product is Abecma (idecabtagene vicleucel), a BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory multiple myeloma in collaboration with Bristol Myers Squibb Company. Founded in 2021 as a spinout from bluebird bio, Inc. and headquartered in Cambridge, Massachusetts, the company previously pursued a broader pipeline targeting hematologic malignancies and solid tumors, including programs for non-Hodgkin lymphoma, acute myeloid leukemia and ovarian cancer. In recent major developments, 2seventy bio divested its R&D pipeline (excluding Abecma) to Regeneron Pharmaceuticals in January 2024 for $5 million upfront, sold additional assets including a hemophilia A program and in vivo gene editing technology to Novo Nordisk in June 2024, implemented workforce reductions to approximately 65 employees and refocused exclusively on Abecma commercialization and development; as of May 13, 2025, it operates as a subsidiary of Bristol Myers Squibb following the latter's $286 million acquisition completed in Q2 2025.
2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT
2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results
2seventy bio, Inc. (TSVT) Upgraded to Buy: Here's Why
2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of 2seventy bio, Inc. - TSVT
Shareholder Alert: The Ademi Firm investigates whether 2seventy bio, Inc. is obtaining a Fair Price for its Public Shareholders
TSVT Up on Acquisition Agreement With BMY for $286 Million
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of 2seventy bio, Inc.
Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal
Top 3 Health Care Stocks That May Keep You Up At Night In Q1
Bristol Myers acquires cell therapy partner 2seventy bio for about $286 million
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb
2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
2seventy bio, Inc. (TSVT) Upgraded to Buy: Here's What You Should Know
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
2seventy bio, Inc. (TSVT) Q3 2024 Earnings Call Transcript
2seventy bio, Inc. (TSVT) Reports Q3 Loss, Lags Revenue Estimates